For a small number of patients, carpal tunnel is an early manifestation of amyloidosis. This study will collect specimen, enabling investigators to screen patients with carpal tunnel syndrome for amyloidosis through an interventional blood draw procedure.
This is an observational, cohort, prospective study that is estimated to include 500 participants in November 2020. It will include a carpal tunnel blood draw group/cohort and a venipuncture blood draw intervention. The investigators hope to determine the number of carpal tunnel syndrome patients identified with amyloidosis. These patients will be categorized as mild, moderate or severe.
- Patients must be within the timeframe of 24 months of confirmed diagnosis of Carpal Tunnel Syndrome
- Individuals ages 18 and older
- Diagnosed carpal tunnel syndrome based on Electromyography (EMG) results
- Electrographic confirmation of median neuropathy at the wrist
- Possess the ability to comprehend and willingness to sign a written informed consent document
- Patients receiving hemodialysis or those with known amyloidosis
This study will take place at the University of Miami and The Ouellette Group Physicians For The Hand in Miami, Florida. For questions and/or concerns, you may contact James Hoffman, MD via phone, at 305-243-4860, or via email, at email@example.com. You may also contact Elizabeth Anne Ouellette, MD, MBA via phone, at 786-457-6706, or via email, at eouellette@TheOuelletteGroup.com
This study is sponsored by the University of Miami with James Hoffman, MD, as the Principal Investigator.